PE20251275A1 - Agentes aglutinantes 5t4 y usos de los mismos - Google Patents

Agentes aglutinantes 5t4 y usos de los mismos

Info

Publication number
PE20251275A1
PE20251275A1 PE2024002518A PE2024002518A PE20251275A1 PE 20251275 A1 PE20251275 A1 PE 20251275A1 PE 2024002518 A PE2024002518 A PE 2024002518A PE 2024002518 A PE2024002518 A PE 2024002518A PE 20251275 A1 PE20251275 A1 PE 20251275A1
Authority
PE
Peru
Prior art keywords
cdr1
cdr2
cdr3
seq
amino acid
Prior art date
Application number
PE2024002518A
Other languages
English (en)
Spanish (es)
Inventor
Bonnie Hammer
Jeffrey N Higaki
Seema Kantak
Charles Kaplan
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20251275A1 publication Critical patent/PE20251275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2024002518A 2022-05-13 2023-05-10 Agentes aglutinantes 5t4 y usos de los mismos PE20251275A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13
PCT/US2023/066819 WO2023220626A2 (en) 2022-05-13 2023-05-10 5t4 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
PE20251275A1 true PE20251275A1 (es) 2025-05-14

Family

ID=88731098

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002518A PE20251275A1 (es) 2022-05-13 2023-05-10 Agentes aglutinantes 5t4 y usos de los mismos

Country Status (16)

Country Link
US (1) US20250326858A1 (enExample)
EP (1) EP4522660A4 (enExample)
JP (1) JP2025518493A (enExample)
KR (1) KR20250024530A (enExample)
CN (2) CN120607619A (enExample)
AU (1) AU2023267764A1 (enExample)
CA (1) CA3252305A1 (enExample)
CL (2) CL2024003442A1 (enExample)
CO (1) CO2024015383A2 (enExample)
CR (1) CR20240489A (enExample)
DO (1) DOP2024000234A (enExample)
IL (1) IL316788A (enExample)
MX (1) MX2024013871A (enExample)
PE (1) PE20251275A1 (enExample)
TW (1) TW202400639A (enExample)
WO (1) WO2023220626A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
US20260008868A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596295A (en) * 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2959694C (en) * 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
CN114025797A (zh) * 2019-05-31 2022-02-08 昆士兰医学研究所理事会 抗Gal9免疫抑制性结合分子

Also Published As

Publication number Publication date
EP4522660A2 (en) 2025-03-19
WO2023220626A3 (en) 2023-12-14
IL316788A (en) 2025-01-01
CL2025002572A1 (es) 2025-10-03
CL2024003442A1 (es) 2025-02-28
WO2023220626A2 (en) 2023-11-16
KR20250024530A (ko) 2025-02-18
MX2024013871A (es) 2024-12-06
US20250326858A1 (en) 2025-10-23
AU2023267764A1 (en) 2024-11-21
CN119546643A (zh) 2025-02-28
CR20240489A (es) 2025-01-07
CN120607619A (zh) 2025-09-09
DOP2024000234A (es) 2025-02-28
TW202400639A (zh) 2024-01-01
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CA3252305A1 (en) 2023-11-16
CO2024015383A2 (es) 2025-02-04

Similar Documents

Publication Publication Date Title
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CN115551889A (zh) 抗cd73抗体及其用途
RU2018100424A (ru) Комбинированная терапия для лечения злокачественной опухоли
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
PE20221262A1 (es) Anticuerpos terapeuticos y sus usos
PE20220575A1 (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
JP2018534933A5 (enExample)
PE20140573A1 (es) Conjugados de anticuerpo-farmaco
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
AR123480A1 (es) Moléculas de unión terapéuticas
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
AU2016250900A1 (en) Therapeutic antibodies and uses thereof
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы
AR099181A1 (es) Métodos para usar anticuerpos anti-steap1 e inmunoconjugados
AR131143A1 (es) Conjugados anticuerpo-fármaco anti-cea y métodos de uso
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
AR120430A1 (es) Células car-t dirigidas a epha3 para el tratamiento de tumores
TW202204424A (zh) 用於人類疾病之治療的ｃｄ３８抗體
US11306153B2 (en) Anti-AXL tyrosine kinase receptor antibodies and uses thereof
JP2022502079A5 (enExample)
MX2025003940A (es) Métodos para tratar cáncer con anticuerpos biespecíficos egfr x cd28 solos o en combinación con anticuerpos anti-pd-1
CR20230473A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.